Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8909 results

  1. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  2. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Luspatercept for treating anaemia caused by myelofibrosis [ID6697]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]

    Awaiting development Reference number: GID-TA11937 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  7. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date:  29 May 2026

    NICE guideline
    In development

  8. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

    Health technology evaluations
    In development

  10. Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    In development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    Awaiting development Reference number: GID-TA11425 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    Awaiting development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Luspatercept for treating haemoglobin H disease [ID6714]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ruxolitinib for Prurigo Nodularis [ID6571]

    Awaiting development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development